Roche hands back rights to NewLink’s immunotherapy
admin 9th June 2017 Uncategorised 0Roche’s Genentech is handing back rights to NewLink Genetic’s investigational immunotherapy navoximod, pushing the latter’s stock down more than 30 percent.
More: Roche hands back rights to NewLink’s immunotherapy
Source: News